Challenges and controversies in resectable non-small cell lung cancer: a clinician's perspective.
Date
2024-03-01ICR Author
Author
Houda, I
Dickhoff, C
Uyl-de Groot, CA
Damhuis, RAM
Reguart, N
Provencio, M
Levy, A
Dziadziuszko, R
Pompili, C
Di Maio, M
Thomas, M
Brunelli, A
Popat, S
Senan, S
Bahce, I
Type
Journal Article
Metadata
Show full item recordAbstract
The treatment landscape of resectable early-stage non-small cell lung cancer (NSCLC) is transforming due to the approval of novel adjuvant and neoadjuvant systemic treatments. The European Medicines Agency (EMA) recently approved adjuvant osimertinib, adjuvant atezolizumab, adjuvant pembrolizumab, and neoadjuvant nivolumab combined with chemotherapy, and the approval of other agents or new indications may follow soon. Despite encouraging results, many unaddressed questions remain. Moreover, the transformed treatment paradigm in resectable NSCLC can pose major challenges to healthcare systems and magnify existing disparities in care as differences in reimbursement may vary across different European countries. This Viewpoint discusses the challenges and controversies in resectable early-stage NSCLC and how existing inequalities in access to these treatments could be addressed.
Collections
Subject
Access to primary care
Adjuvant chemotherapy
Biomarkers
Disease-free survival
Europe
Humans
Immune checkpoint inhibitors
Lung neoplasms
Non-small-cell lung cancer
Protein kinase inhibitors
Surgery
United States
United States Food and Drug Administration
Language
eng
Date accepted
2024-01-08
License start date
2024-03-01
Citation
The Lancet Regional Health - Europe, 2024, 38 pp. 100841 -
Publisher
ELSEVIER